Novartis (SWX:NOVN) Wins FDA Approval For Rhapsido, Is The Discount To Fair Value Still Real?
Novartis (SWX:NOVN) just picked up a fresh FDA approval for Rhapsido, an oral BTK inhibitor now cleared for adults with symptomatic dermographism who are not adequately helped by H1 antihistamines.
For context, Novartis shares last closed at CHF119.3, with a 1 month share price return of 6.48% and a year to date share price gain of 9.95%. The 1 year total shareholder return sits at 18.16% and the 5 year total shareholder return at 97.44%, which hints that interest in the story has been building over time rather than fading on short term news like the latest Rhapsido approval.
Scan other pharmaceutical plays riding similar clinical momentum with the hand picked 223 resilient stocks with low risk scores designed to balance upside potential with more resilient risk profiles.
The Rhapsido lift has pushed Novartis closer to analyst targets, yet the shares still trade at a reported discount to intrinsic value. Is that a genuine margin of safety, or the market pricing in real risks?
Most Popular Narrative: 5% Undervalued
On the most followed view, Novartis screens as undervalued, with a fair value estimate of about CHF126 versus the last close at CHF119.30. This difference creates a clear gap that the narrative aims to explain.
Operational efficiency gains from portfolio streamlining (for example, previous spin offs and exiting non core lines) and productivity improvements are driving core margin expansion and higher free cash flow, which can be reinvested in R&D and shareholder returns, supporting long term earnings and net margin growth.
See why 114 investors see Novartis as 5% undervalued.
Result: Fair Value of CHF126 (UNDERVALUED)
Still, key risks around loss of exclusivity for blockbuster drugs and mounting global pricing pressure could reverse the Novartis undervaluation story.
Find out about the key risks to this Novartis narrative.
Next Steps
Mixed messages in the Novartis story so far. Consider acting while sentiment is divided and weigh the data for yourself through the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Novartis?
Do not stop at Novartis. Broaden your watchlist with fresh ideas filtered by quality, resilience and income potential using the Simply Wall St Screener.
- Target stronger balance sheets by reviewing companies on the list of solid balance sheet and fundamentals (203 results) that pair financial resilience with healthier fundamentals.
- Explore underappreciated potential by scanning the 617 high quality undiscovered gems before other investors focus on the same stories.
- Build a steadier income stream by reviewing the 219 dividend fortresses that focus on higher yields backed by more robust financial profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com